Current Opinion in Neurology, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 26, 2024
Purpose of review Current biological findings provide new insights into the genetics driving growth low-grade gliomas in pediatric patients. This has provided targets for novel therapies. The purpose this paper is to therapies that have been published past 24 months. Recent Low-grade are often driven by mitogen activated protein kinase (MAPK) alterations either with BRAF V600E point mutations or fusions. advances also highlighted fusions fibroblast factor receptor (FGFR), myeloblastosis family transcription factors (MYB), meningioma 1 tumor suppressor (MN1), neurotrophic receptors (NTRK), Kristen RAS (Rat Sarcoma Virus) oncogene homolog mammals (KRAS), Receptor tyrosine ROS proto (ROS1), C alpha (PRKCA), and platelet derive (PDGFR) amplification. Novel employed showing encouraging results gliomas. trials underway newer generation pan RAF inhibitors - (MEK) inhibitors. Other early phase clinical safety data patients targeting FGFR fusion, NTRK PDGFR amplification ROS1 mutations. Summary Historical treatment options utilized surgery, radiation therapy conventional chemotherapy. Recently greater insight their biology found MAPK pathways hallmark tumorigenesis. Targeting these led control shrinkage without use Caution should be taken however, since still novel, we do not fully appreciate long-term effects. Nonetheless a era targeted medicine here.
Language: Английский